Financial Analysis

NOTE 9 COMMITMENTS AND CONTINGENCIES The Company acquires assets still in development and enters R&D arrangements with third parties that often require milestone and royalty payments to the third-party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, contingent upon the successful achievement of an important point in the development lifecycle of the pharmaceutical product (e.g., approval of the product for marketing by a regulatory agency). If required by the license agreements, the Company may have to make royalty payments based upon a percentage of the sales of the pharmaceutical products if regulatory approval for marketing is obtained. For the years ended April 30, 2026 and 2025, the company expensed $ 391,301 and $ 438,416 , respectively, in research and development expenses within the accompanying consolidated statements of operations. There have been no recognized costs related to royalty payments. There are future royalty payments as follows: Four percent royalty on all gross sales received by us or the Companys affiliates; Twenty percent royalty on gross revenues received by us or the Companys affiliates from a sublicense or right to use the patents or the licenses granted by the Company or the Companys affiliates; Fifty percent of any other financial and non-financial consideration received from sublicensees of the Cell-in-a-Box technology; and The removal of all milest …

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

NOTE 6 STOCK OPTIONS AND WARRANTS 2021 Equity Incentive Plan Effective June 30, 2021, the Company implemented the 2021 Equity Incentive Plan (2021 Equity Plan) as approved by the Companys stockholders. The 2021 Equity Plan is administered by the Compensation Committee of the Board and has 166,667 shares authorized under this plan. The 2021 Equity Plan can issue various types of awards, as follows: stock options, stock appreciation rights, restricted stock, restricted stock units, and cash or other stock-based awards. The 2021 Equity Plan is available to be issued to employees, directors, consultants, and other individuals who provide services to the Company. An incentive stock options (ISOs) can only be granted to employees and shall not exceed 10-years (5-years in the case of ISOs granted to any 10% shareholder). As of April 30, 2026, there are 154,596 shares remaining available under this plan. 2022 Equity Incentive Plan Effective December 28, 2022, the Company implemented the 2022 Equity Incentive Plan (2022 Equity Plan) as approved by the Companys stockholders. In October 2025, the Company held a special meeting of stockholders (the 2025 Special Meeting). At the 2025 Special Meeting, the stockholders of the Company approved an amendment to the 2022 Equity Plan which, among other things, increased the number of shares of common stock available for grant under the 2022 Equity Plan by 2,250,000 . In March 2026, at the Companys annual stockholders meeting, the stockholders of …

DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock · excerpt; the full note is in the filing

NOTE 14 FAIR VALUE MEASUREMENTS Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the year ended April 30, 2026 and 2025. The carrying amounts of cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair values at April 30, 2026 and 2025 due to their short-term nature. The fair value of the bifurcated embedded derivative related to the convertible preferred stock was estimated using a Monte Carlo simulation model, which uses as inputs the fair value of the Companys common stock and guideline companies estimates for the equity volatility and traded volume volatility of the Companys common stock, the time maturity of the convertible preferred stock, the risk-free interest rate for a period of time that approximates the time to maturity, dividend rate, a penalty dividend rate and the probability of default. The fair value of the warrant liability was estimated using the Black Scholes Merton Model which uses as inputs the following weighted average assumptions, as noted above: dividend yield, expected terms in years, equity volatility and risk-free rate. Fair Value on a Recurring Basis The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least a …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

NOTE 10 - INCOME TAXES For financial reporting purposes, the net pre-tax book income and/or loss for the U.S. and foreign entities, in the aggregate were: Schedule of net pre-tax book income and/or loss Years Ended April 30, 2026 2025 United States $ (19,424,654 ) $ 30,656,050 Foreign Total $ (19,424,654 ) $ 30,656,050 The Company did no t record income tax expense for federal, state, or foreign for the years ended April 30, 2026 and 2025, respectively. For the years ended April 30, 2026 and 2025, the Company paid no income taxes, net of refunds received, in federal, state, or foreign jurisdictions. Because total income taxes paid, net of refunds received, were zero for each of the years ended April 30, 2026 and 2025, no individual jurisdiction met the 5% disaggregation threshold for separate disclosure. The Company elected to prospectively adopt the guidance in ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The following table reconciles the U.S. federal statutory income tax rate of 21% to the Companys effective income tax rate for the year ended April 30, 2026 in accordance with the guidance in ASU 2023-09: Schedule of effective income tax rate Year Ended April 30, 2026 U.S. federal statutory tax rate $ (4,079,177 ) 21.0 % State income taxes, net of federal income tax effect (1) Foreign tax effects Changes in valuation allowances 2,998,757 (15.4 ) Non-taxable or non-deductible items Fair value of warranty liability 996,688 (5.1 ) Gain on …

IncomeTaxDisclosureTextBlock · excerpt; the full note is in the filing

New Accounting Pronouncements Effective in Future Periods In November 2024, the FASB issued ASU No. 2024-03 (ASU 2024-03), Disaggregation of Income Statement Expenses. The guidance requires additional, disaggregated disclosure about certain income statement expense line items. The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted, and is required to be applied prospectively with the option of retrospective application. The Company is currently evaluating the impact on the consolidated financial statements and related disclosures. In December 2025, the FASB issued ASU 2025-11 Interim Reporting (Topic 270): Narrow-Scope Improvements to improve the guidance in Topic 270, Interim Reporting, by improving the navigability of the required interim disclosures and clarifying when that guidance is applicable. The amendments also provide additional guidance on what disclosures should be provided in interim reporting periods. The guidance is effective for the Companys interim periods within annual reporting periods beginning after December 15, 2027. The Company is evaluating the impact of adoption of this standard on its financial statements and disclosures. …

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

NOTE 8 RELATED PARTY TRANSACTIONS The Company had the following related party transactions during the years ended April 30, 2026 and 2025, respectively. The Company owns 13.8 % of the equity in SG Austria, and this investment is reported on the cost method of accounting. SG Austria has two subsidiaries: (i) Austrianova; and (ii) Austrianova Thailand. The Company did not purchase products and services from these subsidiaries in the years ended April 30, 2026, and 2025, respectively. In April 2014, the Company entered the Vin-de-Bona Consulting Agreement pursuant to which it agreed to provide professional consulting services to the Company. Vin-de-Bona is owned by Prof. Gunzburg and Dr. Salmons, both of whom are involved in numerous aspects of the Companys scientific endeavors relating to cancer (Prof. Gunzburg is the Chairman of Austrianova, and Dr. Salmons is the Chief Executive Officer and President of Austrianova). The term of the agreement is for 12 months, automatically renewable for successive 12-month terms. After the initial term, either party can terminate the agreement by giving the other party 30 days written notice before the effective date of termination. The agreement has been automatically renewed annually. The amounts incurred for the years ended April 30, 2026 and 2025, were approximately $ 10,500 and $ 16,000 , respectively. The Companys Chief Executive Officer was appointed to the Femasys board of directors, see Note 4 Investments in Debt and Equity Securiti …

RelatedPartyTransactionsDisclosureTextBlock · excerpt; the full note is in the filing

NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Basis of Presentation The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through three wholly owned subsidiaries: (i) PharmaCyte Biotech Europe Limited; (ii) PharmaCyte Biotech Australia Pty. Ltd.; and (iii) Viridis Biotech, Inc. and are prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and the Rules and Regulations of the Commission. Upon consolidation, intercompany balances and transactions are eliminated. Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of the Companys consolidated financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Companys consolidated financial position and results of operations. The Companys most significant estimates and assumptions are t …

SignificantAccountingPoliciesTextBlock · excerpt; the full note is in the filing

NOTE 8 COMMITMENTS AND CONTINGENCIES The Company acquires assets still in development and enters R&D arrangements with third parties that often require milestone and royalty payments to the third-party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, contingent upon the successful achievement of an important point in the development lifecycle of the pharmaceutical product (e.g., approval of the product for marketing by a regulatory agency). If required by the license agreements, the Company may have to make royalty payments based upon a percentage of the sales of the pharmaceutical products if regulatory approval for marketing is obtained. For the three and six months ended October 31, 2025 the Company expensed $ 141,085 and $ 236,242 , respectively, and $ 97,470 and $ 193,486 for the three and six months ended October 31, 2024, respectively in research and development expenses within the accompanying unaudited condensed consolidated statements of operations. There have been no recognized costs related to royalty payments. There are future royalty payments as follows: Four percent royalty on all gross sales received by us or the Companys affiliates; Twenty percent royalty on gross revenues received by the Company or the Companys affiliates from a sublicense or right to use the patents or the licenses granted by the Company or the Companys affiliates; Fifty percent of any other fi …

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

NOTE 6 STOCK OPTIONS AND WARRANTS 2021 Equity Incentive Plan Effective June 30, 2021, the Company implemented the 2021 Equity Incentive Plan (2021 Equity Plan) as approved by the Companys stockholders. The 2021 Equity Plan is administered by the Compensation Committee of the Board and has 166,667 shares authorized under this plan. The 2021 Equity Plan can issue various types of awards, as follows: stock options, stock appreciation rights, restricted stock, restricted stock units, and cash or other stock-based awards. The 2021 Equity Plan is available to be issued to employees, directors, consultants, and other individuals who provide services to the Company. An incentive stock options (ISOs) can only be granted to employees and shall not exceed 10-years (5-years in the case of ISOs granted to any 10% shareholder). As of October 31, 2025, there are 154,596 shares remaining available under the 2021 Equity Plan. 2022 Equity Incentive Plan Effective December 28, 2022, the Company implemented the 2022 Equity Incentive Plan (2022 Equity Plan) as approved by the Companys stockholders. In October 2025, the Company held a special meeting of stockholders (the 2025 Special Meeting). At the 2025 Special Meeting, the stockholders of the Company approved an amendment to the 2022 Equity Plan which, among other things, increased the number of shares of common stock available for grant under the 2022 Equity Plan by 2,250,000 . The 2022 Equity Plan is administered by the Compensation Committee …

DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock · excerpt; the full note is in the filing

NOTE 12 FAIR VALUE MEASUREMENTS Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the three and six months ended October 31, 2025. The carrying amounts of cash equivalents, other current assets, accounts payable and accrued expenses approximate their face values at October 31, 2025 due to their short-term nature. The fair value of the bifurcated embedded derivative related to the convertible preferred stock was estimated using a probability-weighted scenario model, which uses as inputs the fair value of the Companys common stock and estimates for the equity volatility and of the Companys common stock, the time to maturity of the convertible preferred stock, the risk-free interest rate for a period of time that approximates the time to maturity, the maturity redemption premium rate, the liquidation premium rate, the market discount rate, and the dividend rate. The fair value of the warrant liability was estimated using the Black Scholes Merton Model which uses as inputs the following weighted average assumptions, as noted above: dividend yield, expected terms in years, equity volatility and risk-free rate. Fair Value on a Recurring Basis The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

New Accounting Pronouncement Effective in Future Periods In December 2025, the FASB issued ASU 2025-11 Interim Reporting (Topic 270): Narrow-Scope Improvements to improve the guidance in Topic 270, Interim Reporting, by improving the navigability of the required interim disclosures and clarifying when that guidance is applicable. The amendments also provide additional guidance on what disclosures should be provided in interim reporting periods. The guidance is effective for the Companys interim periods within annual reporting periods beginning after December 15, 2027. The Company is evaluating the impact of adoption of this standard on its financial statements and disclosures. …

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

NOTE 7 OTHER RELATED PARTY TRANSACTIONS The Company had the following related party transactions during the three and six months ended October 31, 2025 and 2024, respectively. The Company owns 13.9 % of the equity in SG Austria which is presented using the measurement alternative allowed under ASC 321 - Investments Equity Securities with no readily determinable fair values. SG Austria has two subsidiaries: (i) Austrianova; and (ii) Austrianova Thailand. The Company purchased products and services from these entities in the approximate amounts of $0 in the three and six months ended October 31, 2025, and 2024, respectively. The investment in SG Austria was fully impaired as of April 30, 2024. In April 2014, the Company entered the Vin-de-Bona Consulting Agreement pursuant to which it agreed to provide professional consulting services to the Company. Vin-de-Bona is owned by Prof. Gunzburg and Dr. Salmons, both of whom are involved in numerous aspects of the Companys scientific endeavors relating to cancer (Prof. Gunzburg is the Chairman of Austrianova, and Dr. Salmons is the Chief Executive Officer and President of Austrianova). The term of the agreement is for 12 months and is automatically renewable for successive 12-month terms. After the initial term, either party can terminate the agreement by giving the other party 30 days written notice before the effective date of termination. To date, the agreement has been automatically renewed annually. The amounts incurred for the t …

RelatedPartyTransactionsDisclosureTextBlock · excerpt; the full note is in the filing

NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and the rules and regulation of the United States Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair statement of the unaudited condensed consolidated financial statements of the Company as of October 31, 2025 and for the three and six months then ended. The results of operations for the three and six months ended October 31, 2025 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of April 30, 2025 and for the year then ended which are included in the Companys Annual Report on Form 10- K, filed with the SEC on August 11, 2025. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through three wholly owned subsidiaries: (i) PharmaCyte Biotech Europe Limited; …

SignificantAccountingPoliciesTextBlock · excerpt; the full note is in the filing

NOTE 13 SUBSEQUENT EVENTS On November 21, 2025, the Company received $5 million in full settlement of the Femasys Note. Additionally, the Company received 379,747 shares of Femasys common stock in full settlement of the accrued interest of $300,000. The Company holds a total of 695,537 shares of Femasys common stock. In December 2025, the Company received notices of exercise of the Series B Warrants. The Company issued 1,100,000 shares of its common stock and received $1,046,760 in settlement of the exercises. In November and December 2025, the Company received notices of conversion of the Series C preferred convertible stock. The conversions resulted in the issuance of 2,238,381 shares of its common stock and the cancellation of 2,124 Series C Preferred Shares. …

SubsequentEventsTextBlock · excerpt; the full note is in the filing